# Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above

> **NCT07327398** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 1200 (estimated)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza virus split vaccine (0.7mL/vial)
- **BIOLOGICAL:** Influenza virus split vaccine

## Key facts

- **NCT ID:** NCT07327398
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-07
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327398, "Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07327398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*